Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

Super movers aged 80+ and cognitive impairment, decline and brain health

In this abstract, people aged 80+ with unusually fast gait had lower risk of incident cognitive impairment and slower cognitive decline than nonsuper movers; postmortem dementia-related pathologies did not differ. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Super movers are defined as people aged 80 or older with gait speeds at least 1.5 standard deviations above age- and sex-adjusted means. [1]

  2. In the HRS-INS data, super movers had a lower risk of incident cognitive impairment (hazard ratio 0.49, 95% CI 0.28-0.71) over follow-ups of 3.4 to 5.4 years. [1]

  3. In RUSH MAP, super movers had lower Alzheimer disease and dementia prevalence but no differences in postmortem dementia-related pathologies. [1]

The source at a glance

Study type / format
Retrospective study using data from three cohorts, reported in an abstract
Population / context
Adults aged 80 or older without Alzheimer disease or dementia at baseline in three study sources.
Summary based on
Study abstract
Original publication
June 16, 2026

Super movers defined by gait speed at 80+

The abstract defines super movers as people aged 80 or older whose gait speed is at least 1.5 standard deviations above age- and sex-adjusted means. It reports that they tend to have fewer chronic conditions, healthier lifestyles and a younger biological age. The study asked about their risk of incident cognitive impairment, their trajectories of cognitive decline and their brain health.

Supporting source [1]

Lower impairment risk and slower decline in three cohorts

In the Health and Retirement Study International Network of Studies data (n = 3,989; 358 super movers), after excluding 274 adults with cognitive impairment at baseline, super movers had a lower risk of incident cognitive impairment (hazard ratio 0.49, 95% confidence interval 0.28-0.71) over follow-ups of 3.4 to 5.4 years. In the LonGenity Study (n = 197), super movers showed slower memory and non-memory-related cognitive decline and preserved hippocampal volume in specific subfields. In the RUSH Memory Aging Project (n = 692), super movers had better antemortem cognition and lower Alzheimer disease and dementia prevalence, but no differences in postmortem dementia-related pathologies.

Supporting source [1]

Abstract-only scope of the super mover comparison

This explainer is based only on the abstract; the full text was not reviewed. The design is described as retrospective, using data from three study sources. The abstract reports associations, not causes, and does not establish that fast gait or any trait protects against cognitive decline. The discussion proposes investigating behavioral and biological traits of super movers as a possible route to protective mechanisms.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. The design is described as retrospective. Reported associations do not show causation, and the abstract does not establish that fast gait protects against cognitive decline.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Cognitive Aging and Brain Health: A Comparison of Super Movers vs Nonsuper Movers.

Jayakody O, Milman S, Barzilai N, Weiss EF, Wang C, Jin Y, Blumen H, Verghese J. · europepmc.org · June 16, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    gait speeds ≥1.5 SDs above age- and
  2. Finding 2 ↑

    lower risk of incident cognitive impairment (HR
  3. Finding 3 ↑

    no differences in postmortem dementia-related pathologies

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…